FDA's Moheb Nasr Discusses QbD with Emil Ciurczak

Our intrepid contributing editor and editorial advisor, the NIR and PAT expert Emil CIurczak talked with Dr. Nasr about a variety of topics, including the potential impact of downsizings on pharma quality initiatives, FDA inspections in a high-tech future, and harmonization between FDA and EMEA regarding PAT.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments